Cohance Lifesciences Share News - Latest Updates, Live News & More

Latest news about Cohance Lifesciences

Cohance Lifesciences Reports Q2 FY26 Results: Revenue Dips 8% Amid Industry Challenges 2 days ago

Cohance Lifesciences Limited reported Q2 FY26 revenue of ₹5,556.00 million, down 8% YoY due to deferred shipments and destocking. Gross margins improved to 74.6% from 71.3% last year. Adjusted EBITDA was ₹1,289.00 million with 23.2% margins. H1 FY26 revenue grew 1.2% to ₹11,049.00 million. The company faced challenges including pharma destocking and biotech funding slowdown but highlighted positive developments such as FDA approval for a partner's drug and successful execution of a large Phase II order. Despite near-term challenges, Cohance maintains its target of USD 1 billion revenue by 2030 with mid-30s EBITDA margins.

Cohance Lifesciences Reports Mixed H1FY26 Results with Revenue Growth of 1.2% and Improved Gross Margins 2 days ago

Cohance Lifesciences Shares Tumble Following Managing Director's Resignation Oct 29, 2025

Cohance Lifesciences Announces Leadership Changes: MD Resigns, CFO Appointed as Whole-time Director Oct 28, 2025

Cohance Lifesciences Receives OAI Classification from USFDA for Hyderabad Facility Oct 26, 2025

More news about Cohance Lifesciences

22Sept 25

Jusmiral Holdings Offloads 3.41 Crore Cohance Lifesciences Shares, Cuts Stake to 24.15%

Jusmiral Holdings Limited, a promoter of Cohance Lifesciences Limited (formerly Suven Pharmaceuticals), sold 3,41,48,000 shares on September 18, 2025. This reduced their stake from 33.08% to 24.15% (32.75% to 23.91% on a fully diluted basis). The sale proceeds will be used for partial repayment of borrowings under a Notes Purchase Agreement from May 29, 2024. The transaction involved releasing encumbrances related to disposal restrictions and was disclosed in compliance with SEBI Takeover Regulations.

18Sept 25

Cohance Lifesciences Promoter Jusmiral Holdings Offloads 3.41 Crore Shares, Reduces Stake to 24.15%

Jusmiral Holdings Limited, a promoter of Cohance Lifesciences, sold 3,41,48,000 shares (8.93% stake) on September 18, 2025, through an on-market transaction on the National Stock Exchange of India. The sale, worth ₹3093.81 crore, reduced Jusmiral's stake from 33.08% to 24.15%. Proceeds will be used for part payment of borrowings under a previously disclosed Notes Purchase Agreement. The transaction complies with SEBI regulations and has been properly disclosed to stock exchanges.

18Sept 25

Cohance Lifesciences Shares Slump 6% as ₹3,073 Crore Block Deal Executed

Cohance Lifesciences experienced a significant market event with 3.39 crore shares (8.9% equity) changing hands through block deals valued at ₹3,073.00 crore. Jusmiral Holdings sold its 8.9% stake for $350 million at a floor price of ₹900.00 per share, a 6.9% discount to the previous closing price. The transaction includes a 210-day lock-up period for further share sales. The stock price fell over 6% in early trading following the deal. IIFL Capital acted as the book-running lead manager for the transaction.

17Sept 25

Jusmiral Holdings to Offload 5.1% Stake in Cohance Lifesciences via Block Deal

Jusmiral Holdings plans to sell up to 5.1% stake in Cohance Lifesciences through block deals, valued at ₹1,756.00 crore. The floor price is set at ₹900.00 per share, a 6.9% discount to the last closing price. Cohance's stock closed at ₹967.70, down 2.2%, and is trading 9.7% lower year-to-date. A 210-day lock-up period will follow the transaction for additional share sales. Cohance Lifesciences, formerly Suven Pharmaceuticals, is a Hyderabad-based Contract Development & Manufacturing Organisation.

15Sept 25

Cohance Lifesciences' API Facility Aces USFDA CGMP Inspection

Cohance Lifesciences announced that its Active Pharmaceutical Ingredient (API) manufacturing facility in Andhra Pradesh, India, has successfully passed a United States Food and Drug Administration (USFDA) Current Good Manufacturing Practice (CGMP) inspection with zero observations. This achievement demonstrates the facility's compliance with FDA manufacturing standards and quality management systems. The successful inspection enables Cohance Lifesciences to manufacture and supply APIs to the U.S. pharmaceutical market, potentially enhancing its competitive position in the global pharmaceutical supply chain.

11Sept 25

Cohance Lifesciences Aces USFDA Inspection with Zero Observations

Cohance Lifesciences successfully completed a USFDA inspection at its API manufacturing facility in Jaggaiahpet, Andhra Pradesh, with zero Form 483 observations. The inspection, conducted from September 8 to 11, focused on cGMP compliance at the API Unit-1 facility. The company reaffirmed its commitment to maintaining high-quality standards and regulatory compliance in pharmaceutical manufacturing for global markets.

19Aug 25

Cohance Lifesciences Reports 13% Revenue Growth in Q1, Expands Capabilities in Niche Technologies

Cohance Lifesciences Limited, a global CDMO, reported 13% year-over-year revenue growth in Q1. The Pharma CDMO segment grew 1% (over 30% adjusted for inventory destocking), with niche technology revenue share increasing to above 20%. Specialty Chemicals segment grew 28%, while API Plus segment saw 90% growth. The company announced a $10 million investment to expand bioconjugation capacity at Princeton and committed INR 230 million for a CGMP oligonucleotide facility at Nacharam. Cohance reaffirmed its goal of $1 billion revenue by 2030 and expects niche technology revenue share to approach mid-20s by FY26 end.

14Aug 25

Cohance Lifesciences Reports 13% Revenue Growth in Q1, Driven by Niche Technologies

Cohance Lifesciences Limited announced Q1 financial results, showing 13% year-on-year revenue growth to ₹5,493.00 million. Niche technology offerings now account for over 20% of total sales. Gross margins expanded to 73.00% from 68.40% year-on-year. The company is investing in bioconjugation and oligonucleotide facilities, and has secured significant orders. Key leadership appointments include a new CEO for the CDMO business and an External Advisory Board. Cohance maintains its target of USD 1.00 billion revenue by 2030 with mid-30s EBITDA margins.

29Jul 25

Cohance Lifesciences Backs Subsidiary with $16.5 Million Corporate Guarantee

Cohance Lifesciences Limited has extended a $16.50 million corporate guarantee to Citibank N.A. for a $15 million credit facility for its U.S. subsidiary, NJ Bio Inc. The guarantee, valid until June 30, 2028, aims to support NJ Bio's bioconjugation operations for Antibody-Drug Conjugates in New Jersey. This move is expected to enhance Cohance's global Contract Development and Manufacturing Organization capabilities. The transaction was conducted at arm's length, with no promoter group involvement.

28Jul 25

Cohance Lifesciences Appoints Yann D'Herve as CEO of CDMO Division, Effective August 1, 2025

Cohance Lifesciences has named Yann D'Herve as the new CEO of its CDMO business, effective August 1, 2025. D'Herve, with extensive experience in pharmaceuticals and healthcare, previously held senior positions at Evonik. He replaces Dr. Sudhir Kumar Singh, who will step down on July 31, 2025. The appointment aims to accelerate growth in Cohance's CDMO platform, leveraging D'Herve's expertise in global pharmaceutical services.

19Jul 25

Cohance Lifesciences Settles RBI Compliance Matter with ₹8.30 Crore Compounding Fee

Cohance Lifesciences Limited has received a compounding order from the RBI related to past foreign investment transactions in ZCL Chemicals Limited. The order, dated July 18, 2025, addresses alleged violations of foreign exchange rules in 2021. Cohance is required to pay a compounding fee of ₹8.30 crore within 15 days. The company had already provisioned for this amount in its financial statements and states there's no additional financial impact. The matter stems from transactions prior to ZCL's merger with Cohance, which later merged with Suven Pharmaceuticals and was renamed.

20Jun 25

Cohance Lifesciences Divests CR Bio Unit to Chromo Labs for Rs 16 Crore

Cohance Lifesciences has sold its non-core CR Bio unit to Chromo Labs for Rs 16 crore. This strategic divestment is aimed at streamlining operations and focusing on the company's core Contract Development and Manufacturing Organization (CDMO) business. The move is expected to allow Cohance to concentrate resources, improve operational efficiency, and strengthen its position in the CDMO sector.

07May 25

Suven Pharma Set to Rebrand as Cohance Lifesciences Following Government Approval

Suven Pharmaceuticals Limited has received governmental approval to change its name to Cohance Lifesciences. This rebranding initiative marks a significant corporate development for the Indian pharmaceutical company. While specific reasons for the name change were not disclosed, it likely reflects a strategic shift in the company's focus or aspirations within the life sciences sector. The transition may involve updates to corporate materials and legal documents, but is not expected to affect the company's ownership structure or share value.

25Apr 25

Suven Pharma Secures Final Approval for Merger with Cohance Lifesciences

Suven Pharmaceuticals Limited has received final approval for its merger with Cohance Lifesciences, effective from May 1, 2025. The merged entity will operate as Cohance Lifesciences. Shareholders of Cohance Lifesciences will receive 11 equity shares of Suven Pharma for every 295 shares held, with May 8, 2025 set as the record date. The merger has obtained all necessary regulatory clearances, including NCLT approval and foreign investment clearance.

23Apr 25

Suven Pharma Secures Government Approval for Increased Foreign Investment Post-Merger

Suven Pharmaceuticals Limited has obtained approval from the Department of Pharmaceuticals, allowing for potential foreign investment above 74% following its merger with Cohance Lifesciences Limited. This approval, granted on April 22, 2025, is a crucial step in the merger process, which was initially approved by the Board on February 29, 2024. The National Company Law Tribunal sanctioned the Scheme of Amalgamation on March 27, 2025, following shareholder approval on November 28, 2024. The merger's Effective Date will be announced once all conditions are met.

28Mar 25

NCLT Approves Merger of Cohance Lifesciences with Suven Pharma

The National Company Law Tribunal (NCLT) has approved the merger between Cohance Lifesciences Limited and Suven Pharmaceuticals Limited. The merger will be effective from the first day of the month following the fulfillment of all conditions. Shareholders of Cohance will receive 11 shares of Suven for every 295 shares held. The combined entity aims to become a leading diversified CDMO in India, with expanded capabilities, an enhanced customer base, and access to multiple FDA-audited GMP facilities. The merger is expected to bring synergy benefits, accelerating growth and improving margins.